FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Party Drug MDMA Goes to Panel for PTSD

[ Price : $8.95]

Federal Register notice: FDA announces a 6/4 Psychopharmacologic Drugs Advisory Committee meeting to discuss a Lykos Therapeutics ...

Marks OK with Some Gene Accelerated Approval Mistakes

[ Price : $8.95]

CBER director Peter Marks says FDA is working to achieve 90% correct decisions on gene therapy accelerated approvals.

Latest Implied Preemption Case Reviewed

[ Price : $8.95]

Three Winston & Strawn attorneys say that by declining to hear an appeal, the Supreme Court has affirmed that some state law claim...

ORA Reorgs Impact on Drug Inspections: Cavazzoni

[ Price : $8.95]

CDER director Patrizia Cavazzoni provides an update on the reorganization of FDAs Office of Regulatory Affairs (ORA) regarding ins...

Breakthrough Status for Myotonic Dystrophy Therapy

[ Price : $8.95]

FDA grants Avidity Biosciences a breakthrough therapy designation for delpacibart etedesiran and its use in treating myotonic dyst...

FDA on Ongoing Getinge Device Concerns

[ Price : $8.95]

FDA reminds healthcare providers and facilities about the agencys continuing safety and quality concerns with some Getinge/Maquet ...

FDA, EPA, USDA Biotechnology Plan

[ Price : $8.95]

FDA says it has worked with EPA and USDA to develop a biotechnology regulatory reform program as required by a presidential Execut...

FDA Grants, Denies Kaiser 2009 REMS Petition

[ Price : $8.95]

FDA grants in part and denies in part a 14-year-old Kaiser Permanente petition on the development, implementation, and evaluation ...

Orphan Status for Mabwell Esophageal Cancer Drug

[ Price : $8.95]

FDA grants China-based Mabwell an orphan drug designation for its novel Nectin-4-targeting antibody-drug conjugate 9MW2821 for tre...

Bioresearch Monitoring Violations at DBC Research

[ Price : $8.95]

FDA warns Dr. Kevin Bender, doing business as DBC Research in Tamarac, FL, about violations in his conduct of clinical trials.